Advertisement

Notfälle in der Dermatoonkologie

Chapter
  • 1.4k Downloads

Zusammenfassung

Bei der tumorinduzierten Hyperkalzämie kommt es zur tumorzellbedingten bzw. paraneoplastischen Freisetzung von Zytokinen, die – unabhängig von vorliegenden Knochenmetastasen – eine gesteigerte Kalziummobilisierung aus dem Skelett sowie eine vermehrte Kalziumrückresorption in der Niere bewirkt.

Literatur

  1. Boles JM, Dutel JL, Briere J, Mialon P, Robasckiewicz M, Garre M, Briere J (1984) Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53:2425–2429PubMedCrossRefGoogle Scholar
  2. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL (2002) Stereotactic radiosurgery for patients with „radioresistant“ brain metastases. Neurosurgery 51:656–665PubMedGoogle Scholar
  3. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94:2265–2272PubMedCrossRefGoogle Scholar
  4. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499–521PubMedCrossRefGoogle Scholar
  5. Burchardi H, Larsen R, Schuster HP, Suter PM (2004) Die Intensivmedizin. Springer, Berlin Heidelberg New York, S. 596CrossRefGoogle Scholar
  6. Busam KJ, Wolchok J, Jungbluth AA, Chapman P (2004) Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol 31:274–280PubMedCrossRefGoogle Scholar
  7. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11PubMedCrossRefGoogle Scholar
  8. Deppermann KM, Kreuser ED (2006) Intrakavitäre Therapie bei malignem Perikarderguss. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, S. 1055–1060CrossRefGoogle Scholar
  9. Dhir V, Arya V, Malav IC, Suryanarayanan BS, Gupta R, Dey AB (2007) Idiopathic systemic capillary leak syndrome (SCLS): case report and systematic review of cases reported in the last 16 years. Intern Med 46:899–904PubMedCrossRefGoogle Scholar
  10. Dillman RO, Hendrix CS (2003) Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 1:38–48PubMedCrossRefGoogle Scholar
  11. Dubrey S, Grocott-Mason R, Mittal T, Burke M (2008) Massive cardiac invasion by amelanotic melanoma with obstructive clinical features. Postgrad Med J 84:163–166PubMedCrossRefGoogle Scholar
  12. Garbe C, Hauschild A, Volkenandt M et al. (2005) Deutsche Leitlinie: Malignes Melanom. In: Garbe C (Hrsg) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Thieme, Stuttgart, S 23–55Google Scholar
  13. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRefGoogle Scholar
  14. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998–3003PubMedCrossRefGoogle Scholar
  15. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338PubMedCrossRefGoogle Scholar
  16. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, Paul C, Chaoui D, Sigal-Grinberg M, Morel P, Dubertret L, Bachelez H (2009) Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol 161:660–663PubMedCrossRefGoogle Scholar
  17. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP (1999) Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 9:611–613PubMedCrossRefGoogle Scholar
  18. Mahajan A, Nirmal S, English MW, Jenney ME, Lazda ED (2002) Acute tumor lysis syndrome in Hodgkin disease Med Pediatr Oncol 39:69–70PubMedCrossRefGoogle Scholar
  19. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567PubMedGoogle Scholar
  20. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13:97–103PubMedCrossRefGoogle Scholar
  21. Nakayama-Ichiyama S, Yokote T, Iwaki K, Hiraoka N, Hirata Y, Oka S, Akioka T, Miyoshi T, Takayama A, Nishiwaki U, Masuda Y, Tsuji M, Hanafusa T (2011) Hypercalcaemia induced by tumour-derived parathyroid hormone-related protein and multiple cytokines in diffuse large B cell lymphoma, not otherwise specified. Pathology 43:742–745PubMedCrossRefGoogle Scholar
  22. Perez-Gala S, Delgado-Jimenez Y, Goiriz R, Fraga J, Garcia-Diez A, Fernandez-Herrera J (2006) Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma 142:1516–1517Google Scholar
  23. Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ (2003) Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol 61:73–80PubMedCrossRefGoogle Scholar
  24. Possinger K, Schmid P (2006) Hyperkalzämie. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer, Berlin, S. 1109–1113CrossRefGoogle Scholar
  25. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199–207PubMedCrossRefGoogle Scholar
  26. Rate WR, Solin LJ, Turrisi AT (1988) Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 15:859–864PubMedCrossRefGoogle Scholar
  27. Schleucher N, Schmoll HJ, Harstrick (2006) Tumorlysesyndrom. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, S. 1114–1117CrossRefGoogle Scholar
  28. Schwartz RN, Stover L, Dutcher J (2002) Managing toxicities of high-dose interleukin-2. Oncology 11 (Suppl 13):11–20Google Scholar
  29. Sparano DM, Ward RP (2011) Pericarditis and pericardial effusion: management update. Curr Treat Options Cardiovasc Med 13:543–555PubMedCrossRefGoogle Scholar
  30. Trefzer U, Pelzer K, Hofmann MA, Sterry W (2006) Parathyroid hormone-related protein-induced hypercalcaemia in metastatic melanoma. J Eur Acad Dermatol Venereol 20:346–347PubMedCrossRefGoogle Scholar
  31. Wing M (2008) Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol 5:11–15PubMedCrossRefGoogle Scholar
  32. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82:160–165PubMedGoogle Scholar
  33. Wroński M, Arbit E (2000) Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg; 93:9–18PubMedCrossRefGoogle Scholar
  34. Yang B, Lu XC, Yu RL, Chi XH, Zhang WY, Zhu HL, Yuan J, Zhao P (2012) Diagnosis and Treatment of Rituximab-Induced Acute Tumor Lysis Syndrome in Patients With Diffuse Large B-Cell Lymphoma. Am J Med Sci, im DruckGoogle Scholar
  35. Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247–50PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Universitätsklinikum ErlangenHautklinikErlangenDeutschland
  2. 2.Privatpraxis für Dermatologie und Ästhetische MedizinRzany und HundBerlinDeutschland

Personalised recommendations